Avanza Fonder AB Buys 6,566 Shares of Johnson & Johnson $JNJ

Key Points

• Avanza Fonder AB increased its shares in Johnson & Johnson by 2.9% during the second quarter, holding a total of 234,647 shares valued at approximately $35.84 million.
• Johnson & Johnson reported a $2.77 EPS for the last quarter, surpassing analysts' expectations, with revenues increasing by 5.8% year-over-year to $23.74 billion.
• The company announced a quarterly dividend of $1.30, yielding 3.0%, and has a current dividend payout ratio of 55.61%.

Avanza Fonder AB increased its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 2.9% in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 234,647 shares of the company's stock after buying an additional 6,566 shares during the quarter. Johnson & Johnson accounts for about 1.1% of Avanza Fonder AB's portfolio, making the stock its 13th biggest holding. Avanza Fonder AB's holdings in Johnson & Johnson were worth $35,842,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the business. Elios Financial Group Inc. raised its position in shares of Johnson & Johnson by 1.5% during the first quarter. Elios Financial Group Inc. now owns 4,496 shares of the company's stock worth $746,000 after purchasing an additional 66 shares during the period. Atlantic Family Wealth LLC lifted its holdings in Johnson & Johnson by 4.4% during the first quarter. Atlantic Family Wealth LLC now owns 1,603 shares of the company's stock valued at $266,000 after purchasing an additional 67 shares during the last quarter. MBA Advisors LLC grew its stake in Johnson & Johnson by 1.2% in the 1st quarter. MBA Advisors LLC now owns 5,553 shares of the company's stock valued at $921,000 after buying an additional 68 shares in the last quarter. Sovereign Financial Group Inc. lifted its holdings in Johnson & Johnson by 1.8% during the 1st quarter. Sovereign Financial Group Inc. now owns 3,928 shares of the company's stock worth $651,000 after purchasing an additional 69 shares in the last quarter. Finally, Nabity Jensen Investment Management Inc boosted its stake in Johnson & Johnson by 1.5% during the first quarter. Nabity Jensen Investment Management Inc now owns 4,624 shares of the company's stock valued at $767,000 after buying an additional 69 shares during the period. Institutional investors and hedge funds own 69.55% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms have commented on JNJ. UBS Group upped their price target on Johnson & Johnson from $180.00 to $190.00 and gave the company a "buy" rating in a research report on Thursday, July 17th. The Goldman Sachs Group raised their price objective on shares of Johnson & Johnson from $185.00 to $186.00 and gave the company a "buy" rating in a research note on Friday. Barclays boosted their target price on Johnson & Johnson from $165.00 to $176.00 and gave the stock an "equal weight" rating in a research report on Thursday, July 17th. Royal Bank Of Canada upped their target price on shares of Johnson & Johnson from $181.00 to $185.00 and gave the company an "outperform" rating in a report on Thursday, July 17th. Finally, Bank of America lifted their target price on Johnson & Johnson from $161.00 to $175.00 and gave the company a "neutral" rating in a research note on Thursday, July 17th. Two analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and ten have issued a Hold rating to the stock. According to data from MarketBeat, Johnson & Johnson currently has an average rating of "Moderate Buy" and a consensus price target of $178.80.

Johnson & Johnson Stock Down 1.1%

Shares of Johnson & Johnson stock traded down $1.97 during trading on Monday, reaching $174.22. The company's stock had a trading volume of 7,186,784 shares, compared to its average volume of 7,799,981. The company has a 50-day simple moving average of $173.14 and a two-hundred day simple moving average of $161.69. The company has a market cap of $419.58 billion, a price-to-earnings ratio of 18.63, a P/E/G ratio of 2.24 and a beta of 0.40. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $181.16.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, beating analysts' consensus estimates of $2.68 by $0.09. The firm had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The business's quarterly revenue was up 5.8% compared to the same quarter last year. During the same period in the previous year, the company earned $2.82 earnings per share. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. As a group, equities analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th were paid a $1.30 dividend. The ex-dividend date was Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a yield of 3.0%. Johnson & Johnson's payout ratio is currently 55.61%.

Insider Transactions at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the firm's stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the transaction, the executive vice president owned 178,013 shares in the company, valued at $31,652,491.53. This trade represents a 24.08% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 0.16% of the company's stock.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.